Prognostic value of interleukin-6 and interleukin-6 receptor in organ-confined clear-cell renal cell carcinoma: a 5-year conditional cancer-specific survival analysis

Cancer statistics, 2015

(2015) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

EAU Guidelines on Renal Cell Carcinoma: 2014 Update

(2015) Borje Ljungberg et al.   EUROPEAN UROLOGY

A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies

(2015) Brian Rini et al.   LANCET ONCOLOGY

Clinical significance of tumor-derived IL-1β and IL-18 in localized renal cell carcinoma: Associations with recurrence and survival1Contributed equally to this work.

(2015) Le Xu et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Interleukin-6 and its receptors: A highly regulated and dynamic system

(2014) Janina Wolf et al.   CYTOKINE

Interleukin-11 receptor predicts post-operative clinical outcome in patients with early-stage clear-cell renal cell carcinoma

(2014) D. Pan et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

The International Society of Urological Pathology (ISUP) Grading System for Renal Cell Carcinoma and Other Prognostic Parameters

(2013) Brett Delahunt et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Impact of Histologic Subtype on Cancer-specific Survival in Patients with Renal Cell Carcinoma and Tumor Thrombus

(2013) Derya Tilki et al.   EUROPEAN UROLOGY

External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

(2013) Daniel YC Heng et al.   LANCET ONCOLOGY

Features Associated with Recurrence Beyond 5 Years After Nephrectomy and Nephron-Sparing Surgery for Renal Cell Carcinoma: Development and Internal Validation of a Risk Model (PRELANE score) to Predict Late Recurrence Based on a Large Multicenter Database (CORONA/SATURN Project)

(2012) Sabine Brookman-May et al.   EUROPEAN UROLOGY

Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study

(2012) Lauren C Harshman et al.   LANCET ONCOLOGY

Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling

(2011) Simon A. Jones et al.   JOURNAL OF CLINICAL INVESTIGATION

Independent Validation of the 2010 American Joint Committee on Cancer TNM Classification for Renal Cell Carcinoma: Results From a Large, Single Institution Cohort

(2011) Simon P. Kim et al.   JOURNAL OF UROLOGY

Conditional Survival and the Choice of Conditioning Set for Patients With Colon Cancer: An Analysis of NSABP Trials C-03 Through C-07

(2010) Beth A. Zamboni et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study

(2008) N Nishimoto et al.   ANNALS OF THE RHEUMATIC DISEASES